Crestone Pharma

We are developing a novel class of small molecule antibiotics targeting PolC, the replicative DNA polymerase in Gram-positive bacteria. By inhibiting a novel bacterial target, these compounds circumvent existing mechanisms of antibiotic resistance. CRS0540 exhibits broad spectrum activity against all clinically significant Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant Streptococcus pneumoniae (PRSP), Streptococcus pyogenes (Group A strep), Streptococcus agalactiae (Group B strep), vancomycin-resistant Enterococci (VRE), Bacillus anthracis (anthrax), and Listeria monocytogenes.

Remember that when facing health issues, your mental well-being matters too.

Reach out, seek support, and prioritize your mental health. You don't have to go through it alone. 💚

At Crestone we are developing a novel class of small molecule antibiotics targeting PolC, the replicative DNA polymerase in Gram-positive bacteria. By inhibiting a novel bacterial target, these compounds circumvent existing mechanisms of antibiotic resistance.